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AMP-activated protein kinase (AMPK) plays an important role in controlling energy 
homeostasis and is envisioned as a promising target to treat metabolic disorders. In the heart, 
AMPK is involved in short-term regulation and in transcriptional control of proteins involved 
in energy metabolism. Here, we investigated whether deletion of AMPKa2, the main cardiac 
catalytic isoform, alters mitochondrial function and biogenesis. Body weight, heart weight 
and AMPKa1 expression were similar in control littermate and AMPKa2-/- mice. Despite 
normal oxygen consumption in perfused hearts, maximal oxidative capacity, measured using 
saponin permeabilized cardiac fibers, was »30 % lower in AMPKa2-/- mice with octanoate, 
pyruvate or glutamate+malate but not with succinate as substrates, showing an impairment at 
complex-I of the respiratory chain. This effect was associated with a 25% decrease in 
mitochondrial cardiolipin content, the main mitochondrial membrane phospholipid that is 
crucial for complex-I activity, and by a 13% decrease in mitochondrial content of linoleic 
acid, the main fatty acid of cardiolipins. The decrease in cardiolipin content could be 
explained by mRNA down-regulation of rate limiting enzymes of both cardiolipin synthesis 
(CDS2) and remodeling (ALCAT1). These data reveal a new role for AMPKa2 subunit in the 
regulation of cardiac muscle oxidative capacity via cardiolipin homeostasis. 
 
Keywords: AMPK, mitochondria, complex-I, respiration, cardiolipins, fatty acids 
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INTRODUCTION 
AMP-activated protein kinase (AMPK) signaling pathway plays an important role in 
controlling energy homeostasis at the whole body level by responding to hormonal or nutrient 
signals in the central nervous system and peripheral tissues that modulate food intake and 
energy expenditure (1,2). AMPK is an ubiquitous serine/threonine protein kinase activated by 
pathological stimuli, such as oxidative damage, osmotic shock, hypoxia, and glucose 
deprivation, as well as by physiological stimuli such as exercise, muscle contraction, and by 
hormones including leptin and adiponectin (3). It exists in cells as a heterotrimeric complex 
composed of a catalytic subunit (a) and two regulatory subunits (b and g). Two a subunit 
isoforms exist, a1 and a2, a2 being the chief isoform expressed in striated muscle, 
accounting for 70-80% of the total AMPK catalytic activity in this tissue (4,5). Activation of 
AMPK causes up-regulation of ATP-producing catabolic pathways and down-regulation of 
ATP-consuming processes (3,6). It is activated in response to decreased cellular energy 
charge (high AMP/ATP ratio) and is involved in regulating carbohydrate and fat metabolism 
(3,5). AMPK acutely modulates mitochondrial oxidative flux via phosphorylation of Acetyl 
CoA carboxylase (ACC), decreasing malonyl-CoA levels and increasing oxidative flux 
through the mitochondrial carnitine palmitoyl transferase 1 (CPT-1) (1-3,5). It also increases 
glucose transport (7) and stimulates glycolysis by activating phosphofructokinase 2 (8). As 
such it is envisioned as a promising target to treat metabolic disorders such as metabolic 
syndrome, obesity and type 2 diabetes.  
Such patients have increased susceptibility to cardiovascular disorders. The role of 
AMPK in the heart is not fully understood. Whereas AMPK is activated during pressure 
overload and exercise induced hypertrophy (9,10), it mediates the antihypertrophic effects of 
adiponectin (11). AMPK is involved in regulating carbohydrate and fatty acid transport 
notably during cardiac ischemia and reperfusion (5,8,12,13). As the final steps of 
carbohydrate and lipid oxidation take place in mitochondria, it is very probable that this 
enzyme also plays a role in mitochondrial substrate oxidation pathways.  
AMPK can also affect energy metabolism through changes in gene expression. It is 
involved in skeletal muscle adaptation to exercise by increasing the expression of the 
peroxisome proliferator activated-receptor g -coactivator-1a (PGC-1a) and activating 
mitochondrial biogenesis but again nothing is known concerning cardiac muscle (14). The 
aim of the present study was to investigate the possible involvement of AMPK in the control 
of cardiac mitochondrial function and biogenesis using specific AMPKa2 deficient mice (15). 
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These mice exhibit normal echocardiographic and hemodynamic characteristics but have 
altered glucose metabolism and a worse metabolic adaptation to ischemia (16). 
 
RESEARCH DESIGN AND METHODS 
Animals 
The generation of AMPKa2-/- mice has been described elsewhere (15). Ten month old 
male AMPKa2-/- (n= 27) and control (n=25) littermate mice were used. Animals were housed 
under temperature-controlled conditions (21°C) and had free access to water and to a standard 
mouse chow. All procedures were performed in accordance with the principles and guidelines 
established by the European Convention for the Protection of Laboratory Animals. Mice were 
sacrificed by lethal intraperitoneal injection of pentothal (150mg/kg), for mitochondrial 
respiration experiments and tissue storage. Left ventricular tissue was isolated, part of which 
was immediately used for mitochondrial function measurement and part of which was rapidly 
frozen and kept at –80° C. 
Perfused Hearts 
Additional mice were anesthetized with urethane (2g/kg). Hearts were quickly removed 
and retrogradely perfused at a constant flow of 2.5 ml/min in the isovolumic Langendorff 
perfused mode without pacing. They were first equilibrated with 11mmol/L glucose for 30 
minutes and then, with 5mM glucose and 0.4mM oleate prebound to 1% BSA as substrates 
for 20 more minutes. Left ventricular pressure was monitored from a water-filled balloon 
introduced in the left ventricle. Oxygen consumption (QO2) was calculated from the 
difference in oxygen content between incoming (aortic) and outcoming (pulmonary artery) 
perfusates (17).  
Electron microscopy 
Left ventricular wall and papillary muscles were quickly isolated in oxygenated buffered 
Krebs solution without calcium to avoid ischemia, and fixed with 2% glutaraldehyde as 
previously described (18). For stereological analysis, papillary muscles were used to ensure 
longitudinal sections, and 3 randomly selected levels separated by more than 50 microns were 
used. From randomly selected cardiomyocytes (12-14 myocytes from each animal) the 
volume density of organelles was estimated by the point counting method (18). The volume 
density Vv of the organelles was estimated as Vv = p/P (p is the number of the test points 
hitting the image of the cellular components, P is the number of all points falling on the 
cardiomyocytes).  
H
AL author m
anuscript    inserm
-00150990, version 1
  
5 
Study of in situ mitochondrial respiration 
Oxygen consumption measurements of saponin-skinned fibers from left ventricle have 
been described previously (19,20). Rates of respiration are given in µmoles O2.min-1.g dry 
weight-1 (dw). 
Two different experimental protocols were used based on substrate utilization pathways 
(Figure 1). The first protocol determined the sensitivity of mitochondrial respiration to 
various substrates in the presence of 2mmol/l ADP, by cumulative substrate addition as 
described previously (21). The second protocol was aimed at determining the dependency of 
respiration on external [ADP] and [creatine] (22), with glutamate+malate as substrates. 
Respiration through complex-III was designed according to (23). 
Biochemical studies 
Frozen tissue samples were weighed, homogenized in ice-cold buffer and enzyme 
activities were determined as described previously (24). Complex-I activity was measured in 
heart homogenized in ice-cold buffer containing Tris Base 10mmol/l (pH 7.2), sucrose 
75mmol/l, mannitol 225mmol/l, EDTA 100µmol/l, and Triton-X100 0.1%. To measure 
NADH-CoQ reductase activity with decyl-ubiquinone as electron acceptor, samples were 
incubated in phosphate buffer 25mmol/l pH 7.5, BSA 2.5mg/ml, decyl-ubiquinone 100µmol/l 
at 30°C. Activity was reported as rotenone-insensitive decrease in NADH absorbance at 
340nm. NADH-ferricyanide reductase activity was measured with ferricyanide as electron 
acceptor and the decrease in absorbance was followed at 410nm.  
Real-Time Quantitative RT-PCR Analysis 
Total muscle RNA was extracted using standard procedures. Real-time RT-PCR was 
performed using the SYBRâGreen method on a LightCycler rapid thermal cycler (Roche 
Diagnostics) as previously described (25). Values of each gene were normalized to cycA 
mRNA content and then corrected for the amount of RNA relative to muscle weight. Primers 
are listed in Table 1. 
Western Blot Analysis 
Specific antibodies were used to measure the protein content of the oxoglutarate/malate 
carrier (OMC) (26) (kind gift from Thomas Scholz and Stacia Koppenhafer, University of 
Iowa, USA), AMPKa1 and AMPKa2 (Upstate Biotechnology Inc., Lake Placid, New York, 
USA) in control and AMPKa2-/- mice. 
Mitochondrial isolation and cardiolipin quantification  
Mitochondria were isolated from cardiac ventricles of control and AMPKa2-/- mice 
according to Moreno-Sanchez et al (27). Cardiolipin was quantified by the spectrophotometric 
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method of Petit et al (28), using the high affinity of 10N-nonyl acridine orange (NAO) for 
cardiolipin of freshly isolated mitochondria. 
Fatty Acid Composition 
Lipids were extracted from heart, isolated cardiac mitochondria, liver and plasma in 2:1 
chloroform-methanol. Phospholipids were separated from non-phosphorous lipids on silica 
acid cartridges, and fatty acids were trans-methylated with BF3-methanol. Methyl esters were 
analyzed by gas chromatography on an Econo-cap EC-WAX capillary column (0.32x30m, 
Alltech Associates) coupled to a flame ionization detector using C17:0 as the internal 
standard as previously described (29). 
Statistical analysis 
Data are expressed as mean ± SEM. Student’s t-test was used to determine the statistical 
significance of differences between group means. Statistical significance was defined as 
P<0.05. 
 
RESULTS 
General characteristics and base-line cardiac function 
AMPKa2-/- mice had normal body (32±1 in control versus 37±3 g) and heart (187±8 in 
control versus 197±16 mg) weights, indicating that cardiac atrophy or hypertrophy were not 
present. Neither left ventricular pressure, or heart rate, or oxygen consumption of isolated 
hearts differed between control and AMPKa2-/- mice whether glucose, or glucose+oleate 
where used as substrates, suggesting that AMKPa2 deficiency does not alter cardiac work 
during normal perfusion (Table 2).  
AMPKa1 protein content (as measured by Western blotting, not shown) was the same in 
control and AMPKa2-/- mice (1.24±0.12 in control versus 1.49±0.21 a.u.). Thus the deficiency 
in AMPKa2 was not compensated for by AMPKa1 overexpression.  
Ultrastructure of the cardiomyocytes 
In control cardiomyocytes, mitochondria formed longitudinal rows under sarcolemma and 
between myofibrils (Figures 2A and 2B). In contrast, in AMPKa2-/- cardiomyocytes from 
both papillary and ventricular muscles, splitting of myofibrils was frequently observed 
(Figure 2C-F). No change in total mitochondrial volume was observed (Table 3), but 
mitochondria lost their ellipsoid shape and became irregular in size (Figures 2C-F). They lost 
their arrangement in longitudinal rows and formed large and spread clusters especially under 
the sarcolemma (2D and 2F), so that the volume density of subsarcolemmal mitochondria was 
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increased (SS) while that of intermyofibrillar mitochondria (IM) was decreased (Table 3). No 
change in the volume of lipid droplets was observed (0.97±0.22 in control versus 0.79±0.61 
%).  
Cardiac mitochondrial function 
Respiration rates for almost all substrates were significantly lower in cardiac fibers of 
AMPKa2-/- mice (Figure 3A). Compared to controls, respiration was decreased by 35% with 
malate, 34% following addition of octanoyl-carnitine, 38% after addition of pyruvate and 
31% after final addition of glutamate in AMPKa2-/- mice, but did not change with glycerol-3-
phosphate (G3P). 
Respiration in the presence of phosphate acceptors, ADP and creatine, was studied with 
glutamate+malate (Vglu+mal) as substrates (Table 3). Basal respiration rate (V0) and acceptor 
control ratio (ACR=Vglu+mal/V0) were similar in control and AMPKa2-/- cardiac fibers. No 
difference was observed between the two groups for the affinity for ADP with or without 
creatine. The maximal oxygen-consumption rate was again 24% lower with glutamate+malate 
in the AMPKa2-/- mice (Table 3 and Figure 3). To determine at which point the respiratory 
chain was altered in AMPKa2-/- mice, complex-I was inhibited by amobarbital and respiration 
through complex-II was measured with succinate (Vsuc). Under succinate, no significant 
difference between the two groups was observed, whereas the ratio between complex-I- and 
complex-II-stimulated respiration (Vsuc/Vglu+mal) was increased by 42% in AMPKa2-/- 
mice (Table 3 and Figure 3B). No difference was observed for complex-III activated 
respiration with duroquinol (Vduroq). Thus, AMPKa2 deficiency induces a defect in 
mitochondrial respiration that appears limited to complex-I. 
Energy metabolism enzymes 
In order to understand the origin of mitochondrial defects, activities of key enzymes of 
energy metabolism were assessed (Table 3). Activity of citrate synthase, an index of 
mitochondrial mass, was similar in the two groups of mice. Other enzymes of the energy 
metabolism, total creatine kinase (CK), mitochondrial (mi-CK), adenylate kinase, total lactate 
dehydrogenase (LDH), and cytochrome c oxidase (COX) activities also remained unchanged 
in AMPKa2-/-. Despite decreased respiration through complex-I, maximal complex-I and 
complex-II activities determined in tissue extracts were the same in both groups. To ensure 
that maximal complex-I activity was preserved in AMPKa2-/-, we measured its activity using 
different electron acceptors, but no difference between the two groups was observed 
suggesting that AMPK deficiency did not affect mitochondrial enzyme content.  
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In an attempt to understand the origin of the decreased respiration through complex-I, 
malate-aspartate shuttle enzymes were measured (Table 3). Total malate dehydrogenase 
(MDH), mitochondrial MDH and the amount of OMC (6.8±1.2 (n=6) in control versus 
5.1±0.5 a.u. in AMPKa2-/- (n=6), not shown) were unchanged in AMPKa2 deficient mice. 
Moreover, the mRNA levels of PGC-1a, the main regulator of mitochondrial biogenesis was 
similar in AMPKa2-/- and control hearts (Figure 4B), consistent with the preserved 
mitochondrial enzyme activities. 
Cardiolipins and fatty acid composition 
Complex-I activity in situ is critically dependent on the cardiolipin environment 
(30,31). In AMPKa2-/- mice, the amount of cardiolipin was 25% lower than in controls 
(Figure 4A). In addition, as evidenced in Table 4, the fatty acid composition of whole heart 
phospholipids and of isolated cardiac mitochondria in the AMPKa2-/- mice showed a 
significant decrease in linoleic acid proportion (~80 % of cardiolipin fatty acids). Conversely, 
linoleic acid was significantly increased in the non-phosphorous lipid fraction (which mainly 
contains storage triacylglycerol) of the whole heart homogenate. This decrease in linoleic acid 
content was specific to the heart since it neither decreased in liver phospholipids (19.4±0.8% 
and 19.6±1.1%, control versus AMPKa2-/-) nor in plasma lipids (31.3±0.4% and 27.8±2.2%, 
respectively). 
The level of expression of enzymes involved in cardiolipin homeostasis was 
determined (Figure 4B). Levels of CDS2, the enzyme that catalyzes the initial key step of 
cardiolipin synthesis, i.e. the conversion of phosphatidic acid to CDP-diacylglycerol, as well 
as of ALCAT1, an acyl-CoA:lysocardiolipin acyltransferase implicated in rapid cardiolipin 
remodeling (32,33), were significantly decreased in AMPKa2-/- mice while mRNA content of 
taffazin (TAZ), another phospholipid acyltransferase was unchanged. Interestingly, 
expression of CPT-1, the mitochondrial middle- and long-chain fatty acid transporter, was 
also significantly decreased in AMPK deficient mice. 
 
DISCUSSION 
The main results of this study can be summarized as follows. 1) Specific deficiency in 
AMPKa2 catalytic subunit did not induce cardiac atrophy or hypertrophy. 2) Oxygen 
consumption of isolated perfused heart was normal but mitochondrial ultrastructure was 
altered. 3) AMPK deficiency induced a decrease in maximal oxidative capacity of the cardiac 
muscle, whether lipids, pyruvate or glutamate+malate were used as substrates. 4) This was not 
H
AL author m
anuscript    inserm
-00150990, version 1
  
9 
accompanied by changes in mitochondrial enzyme activities, the malate/aspartate shuttle or 
isolated complex-I or II in vitro activities. 5) When succinate was used as substrate, 
mitochondrial respiration was normal in AMPKa2-/- cardiac fibers, suggesting a defect in 
complex-I function in situ. 6) Cardiolipin content of AMPKa2-/- cardiac mitochondria was 
decreased by 25%, consistent with the altered ultrastructure and the functional defect of 
mitochondrial respiration by complex-I. 7) This defect was accompanied by a significant 
decrease in linoleic acid content of mitochondrial phospholipids and 8) could be explained by 
the decrease in the expression of key enzymes of cardiolipin biosynthesis and remodeling. 
Altogether these results suggest that AMPKa2 is involved in the control of mitochondrial 
respiration through cardiolipin homeostasis.  
AMPKa2-/- mice exhibit perturbation in whole body insulin sensitivity, probably 
modulated by the sympathetic nervous system (15). These mice show normal cardiac content 
in AMPKa1 isoform suggesting that remnant AMPKa1 is unable to compensate for the lack 
of AMPKa2 (16).  
A role for AMPK in controlling cardiac weight is still controversial. While AMPK 
was suggested to play a role in pressure overload hypertrophy (9), it was recently reported 
that adiponectin blocks cardiac hypertrophy by an AMPK dependent mechanism (11). Hearts 
of mice expressing of a dominant negative mutant of AMPKa2 exhibiting a residual 
AMPKa2 activity have preserved weight and baseline function (13). In another model, 
overexpressing a kinase-dead rat a2 isoform, the a2 protein content and activity were absent, 
and a1 content and activity were also decreased, the remnant a1 activity being attributed to 
endothelial cells (12). These mice exhibit a slightly decreased cardiac weight and 
contractility. However, we show here that AMPKa2-/- mice had normal cardiac weight. This 
suggests that the a2 subunit by itself is not essential for cardiac growth. 
Oxygen consumption and contractile function were not different under basal 
conditions either with glucose or glucose plus oleate as substrates, as already described with 
glucose and pyruvate (16) in this mouse line. In KD mutant mice, cardiac function is slightly 
depressed at baseline (12). This difference could be due to the decreased AMPKa1 activity in 
this line. However, the workload of hearts perfused in the Langendorff mode is significantly 
less than in the working mode or in vivo and oxygen consumption does not reach maximal 
capacity. 
To assess maximal mitochondrial function, respiration rates were measured in skinned 
fibers with saturating amounts of substrates, oxygen and phosphate acceptor. Depending upon 
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available substrates and cardiac demand, mitochondria are able to use acetyl-CoA produced 
from pyruvate by pyruvate dehydrogenase downwards of glycolysis, and/or acetyl-CoA 
produced by the b-oxidation of fatty acids, which enters the Krebs cycle (Figure 1). 
Mitochondria can also slightly use G3P by mitochondrial glycerophosphate dehydrogenase, 
which produces FADH2 that enters the respiratory chain directly at the level of complex-II 
(34). We found a clear decrease in the respiration rate of AMPKa2-/- cardiac fibers, whether 
carbohydrate- or lipid-derived substrates were used. This suggests that AMPKa2 is involved 
in the control of cardiac oxidative capacity and in mitochondrial substrate utilization. 
Decreased energy availability in AMPKa2-/- mice would probably occur only at maximal 
workloads, so that the mitochondrial alterations observed here might be more evident during 
heavy exercise or under pathologic stress.  
In order to understand the decrease in respiration of cardiac fibers, we looked at 
indicators of mitochondrial activity. In AMPKa2-/- mouse heart, levels of CS, a marker of 
mitochondrial mass, of COX, an enzyme of the respiratory chain, of mitochondrial creatine 
kinase (mi-CK), a phosphotransfer kinase, and of markers of the malate/aspartate shuttle, 
involved in glutamate+malate utilization, were normal. Additionally, PGC-1a, that induces 
mitochondrial biogenesis (35), and total mitochondrial volume density were unchanged as 
was also observed in skeletal muscles of mice with dominant negative mutant of AMPK (36). 
All this suggests that AMPKa2 is not essential for determining and maintaining 
mitochondrial mass in skeletal and cardiac muscle. However, it may play a role in cardiac 
mitochondrial biogenesis induced by external stimulus as was observed in skeletal muscle in 
response to exercise or chronic energy depletion (36). 
Mitochondrial function also depends on the sensitivity to ADP and to creatine, the 
final acceptor of high-energy phosphates in cardiac mitochondria (37). No change in the 
sensitivity of respiration to ADP and creatine was observed, showing that the efficiency of 
cardiac mitochondria in phosphorylating ADP and producing phosphocreatine was not 
affected by AMPKa2 loss.  
In order to explain the decreased respiration with preserved enzyme activities, we 
compared the respiration rates during activation from complex-I, or -II or -III (Figure 1 and 3, 
Table 2). Respiration with glutamate+malate mainly produces NADH that activates 
respiration through complex-I, while succinate oxidation mainly produces FADH2 that is 
further oxidized by complex-II. Compared with controls, respiration was lower in AMPKa2-/- 
mice with glutamate+malate, but was normal with succinate, revealing an inhibition of 
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complex-I in these animals. Interestingly, respiration from G3P, which produces only FADH2, 
was normal in AMPKa2-/- mice, while it was decreased for NADH producing substrates: 
pyruvate, octanoyl-carnitine. Moreover, respiration through complex-III was unchanged in 
AMPKa2-/- mice. 
Despite a 24% decrease in respiration rate through complex-I, complex-I activity 
measured in total heart extracts was normal in AMPKa2-/- mice, independent of the electron 
acceptor. This indicated that the activity of isolated complex-I was not affected by AMPKa2 
deficiency, suggesting an alteration of the in situ regulation of complex-I by cardiolipin. 
Indeed, activity of the complexes of the respiratory chain, and particularly of complex-I, 
strongly depends on the surrounding phospholipid environment of the inner mitochondrial 
membrane. Cardiolipin is the main functional phospholipid of the mitochondrial inner 
membrane, being present almost exclusively in mitochondria and representing 8-15% of the 
entire cardiac phospholipid mass. A 25% lower mitochondrial cardiolipin content was 
observed in AMPKa2-/- mice. Cardiolipin content is critical for the adaptation of energy 
metabolism to demand. It rises with increased metabolic rate or muscle performance (38), and 
plays a key role in the activity of several inner membrane proteins including complex-I (for 
review see (39)). Both complex-I and III were shown to require cardiolipin but, while being 
necessary for full complex-I activity (40), cardiolipin plays a structural rather than catalytic 
role for complex-III (41). Accordingly, respiration through complex-I but not complex-III 
was decreased in AMPKa2-/- mice. Interestingly, in CHO cells, similar decrease in cardiolipin 
content induces similar alteration in complex-I activity in the respiratory chain without 
changes in isolated, complex-II, complex-III and IV and NADH-reductase activity (31). 
Mitochondrial creatine kinase binding in the vicinity of translocase is dependent on 
cardiolipin environment (42). It is possible that the rather small decrease in cardiolipin 
observed here was not sufficient to affect mi-CK function and activity. 
Examination of cardiac ultrastructure of AMPKa2-/- mice revealed abnormal structure 
of mitochondria of various sizes, arranged in clusters under the sarcolemma and less in 
regular rows between myofilaments as in control hearts. While unchanged total mitochondrial 
volume was in accordance with preserved mitochondrial enzyme activity and PGC-1a 
expression, partial relocation of mitochondria from myofibrillar to subsarcolemmal space 
occurred. No evidence of ultrastructural changes was observed in AMPK KD mutant (12). 
However, in the present study these morphological changes were observed at higher 
magnification and could be more pronounced in older animals. Similarly in CHO cells, an 
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alteration of mitochondrial ultrastructure is specifically associated with reduction in 
cardiolipin content (31). Moreover, although to a lower extent, this resembles the 
ultrastructural abnormalities of mitochondria in the Barth syndrome, an X-linked disease. 
This disease, due to mutations in the tafazzin gene that belongs to the superfamily of 
phospholipid acyltransferase, is characterized by a dramatic reduction in cardiolipin content, 
and by abnormal mitochondrial ultrastructure (43). 
Cardiolipin is the only phospholipid with four acyl chains, ~80% of which are 
composed of linoleic acid (18:2w6), a polyunsaturated fatty acid of the w6 series. The 
decrease in cardiolipin content in AMPKa2-/- heart was accompanied by a significant 
decrease in linoleic acid content of mitochondrial and whole heart phospholipids. The 
decrease in mitochondrial membrane linoleic acid observed in this study is neither due to 
nutritional differences since animals received the same chow diet, nor to a systemic effect 
since the plasma and liver lipid composition was unchanged. The fact that (i) the linoleic acid 
decrease parallels the cardiolipin decrease, (ii) cardiolipin contains approximately 80% 
linoleic acid, and (iii) the linoleic acid content in storage lipids was higher, suggests that the 
decrease in linoleic acid is a consequence rather than a cause of the cardiolipin decrease in 
AMPKa2 deficient mice. The lower linoleic acid content in heart compared to liver of 
AMPKa2-/- mice could be related to the higher proportion of AMPKa1 in liver (4). These 
animals are thus characterized by a dysfunction of cardiac cardiolipin homeostasis that affects 
the inner mitochondrial membrane and that could be the key effector of mitochondrial 
dysfunction.  
Similar decreases in cardiolipin content and complex-I activity were reported 
following partial inhibition of cardiolipin synthesis in CHO cells (31). One important rate-
limiting step of de novo cardiolipin synthesis is the initial reaction catalyzed by CTP:PA 
cytidylyltransferases (also called CDS) (33). In AMPKa2-/- mice expression of CDS2, the 
only cardiac isoform (44) is decreased, possibly explaining the decrease in cardiolipin 
content. A second mechanism of cardiolipin biosynthesis is through deacylation-reacylation 
which is catalyzed by phospholipases and acyltransferases, that are regarded as the principal 
enzymes involved in phospholipid remodeling in mammalian tissues (33). The acyltransferase 
ALCAT1 is regulated in concert with the level of cardiolipin and cardiolipin biosynthesis in 
mammalian heart (32,45). ALCAT1 mRNA expression was decreased in AMPKa2-/- mice 
like both CDS2 mRNA and cardiolipin content. All this suggests that AMPK is involved in 
cardiolipin homeostasis at least at the transcriptional level. Finally, expression of the 
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mitochondrial fatty acid transporter CPT-1 was also decreased in AMPKa2 deficient mice. 
Decreased activation of CPT-1 due to the lack of AMPK-modulated regulation of malonyl 
CoA content, together with the down-regulation of CPT-1, would have an additive inhibitory 
effect on fatty acid oxidation in AMPKa2-/- mice. 
In summary, selective deficiency of AMPKa2 causes a significant decrease in 
maximal mitochondrial respiration, whether carbohydrates or lipids were used as substrates. 
This is due to a defect in the function of complex-I of the respiratory chain within the inner 
mitochondrial membrane, probably due to the decrease in cardiolipin content. Interestingly, it 
has been recently reported that the diabetic heart, characterized by altered lipid homeostasis 
and mitochondrial dysfunction, exhibit a dramatic decrease in cardiolipin content (46). These 
findings suggest that AMPK plays a critical role in the control of cardiac phospholipid 
homeostasis, possibly by modulating their metabolism through transcriptional machinery. 
More work is needed to elucidate the precise mechanisms by which AMPK may enhance 
energy production by favoring cardiolipin synthesis and thus improving the efficiency of the 
respiratory chain.  
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FIGURE LEGENDS 
 
Figure 1: Substrate utilization by cardiac mitochondria. Pyruvate enters the Krebs cycle 
by pyruvate dehydrogenase (PDH), producing acetyl-CoA (Ac-CoA). Octanoyl-carnitine 
undergoes b-oxidation and produces acetyl-CoA, NADH and FADH2. Malate enters 
mitochondria through oxoglutarate/malate carrier (OMC) and produces mainly NADH by 
mitochondrial malate dehydrogenase (mMDH), while glycerol-3 phosphate (G3P) produces 
FADH2 by the mitochondrial glycerol-phosphate dehydrogenase (mGDH). Succinate 
produces mainly FADH2 that enters the respiratory chain through complex-II. NADH is 
reoxidized in the respiratory chain at complex-I and FADH2 at complex-II. 
 
Figure 2: Electron microscopic images of left ventricle and papillary muscles from 
control (A, B) and AMPKa2-/- (C-F) mice. (A) Overview of a control myocyte in 
longitudinal section, with mitochondria and myofibrils arranged in regular longitudinal 
columns. (C and E) Longitudinal section of cardiomyocytes from papillary (C) and 
ventricular (E) muscles from AMPKa2-/- mice showing myofibrillar disorganization, and 
irregular arrangement of intermyofibrillar mitochondria with clusters of mitochondria of 
variable size. (B) Detail of sarcomeres in a control myocyte, showing mitochondria tightly 
packed along sarcomeres. (D and F) Details of sarcomeres in AMPKa2-/- myocytes from 
papillary (D) and ventricular (F) muscles, showing dense packing of mitochondria of irregular 
size. Asterisk: large mitochondria having irregular shape. Arrows: splitting of myofibrils. 
Arrowhead: dividing mitochondrion.  
 
Figure 3. A. Decreased substrate utilization by cardiac mitochondria in AMPKa2-/- 
mice. Respiration rates were measured during the cumulative addition of substrates in 
saponin-skinned cardiac fibers of control and AMPKa2-/- mice. VO2: rate of O2 consumption 
in µmol.min-1.g dw-1. G3P: glycerol-3-phosphate, Mal: malate, Oct: octanoyl-carnitine, Pyr: 
pyruvate, Glu: glutamate. * p<0.05 versus control. B. Respiration rate through complex-I is 
specifically inhibited in AMPKa2-/- mouse heart. VO2: Rate of O2 consumption in 
µmol.min-1.g dw-1 in saponin-permeabilized cardiac fibers. Complex-I: respiration with 
2mmol/l malate and 5mmol/l glutamate. Complex-II: respiration with 10mmol/l succinate. * 
p<0.05 versus control.  
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Figure 4. A. Cardiolipin content is decreased in AMPKa2-/- mice mitochondria. Data 
obtained by colorimetric assay with the NAO (10-N-nonyl acridine orange) in cardiac muscle 
of AMPKa2-/- (n=6) and littermate (n=6) mice in nmoles per mg of mitochondrial proteins. * 
p<0.05 versus control. B. Gene expression. Real-time quantitative RT-PCR analysis of 
mRNA expression of peroxisome proliferator activated-receptor g -coactivator-1a (PGC-1a), 
CTP:PA cytidylyltransferase (CDS2), carnitine palmitoyl transferase 1 (CPT-1), tafazzin 
(TAZ) and acyl-CoA:lysocardiolipin acyltransferase 1 (ALCAT1) in cardiac muscle of 
AMPKa2-/- (n=6) and littermate (n=6) mice. Results are given as means ± S.E.M. in arbitrary 
unit (a.u.) normalized to Cyclophilin A transcription and corrected for the amount of total 
RNA relative to muscle weight. 
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Table 1. Primers used for real-time PCR amplification 
Forward Primer (5'-3’) Gene GenBank accession number Reverse Primer (5'-3’) PCR product size (bp) 
CACCAAACCCACAGAGAACAG 
PGC-1a NM_008904 GCAGTTCCAGAGAGTTCCACA 
210 
CGGTTCATCTCCTTTGCCC CDS2 NM_138651 GATGACGCACGAGATGGGA 
201 
TCACCTGGGCTACACGGAGA CPT-1 NM_009948 TCGGGGCTGGTCCTACACTT 
219 
TTGGACGGCTGATTGCTGAG TAZ NM_181516 TGTGAGGGCTTTCCGCATCT 
215 
GGAAGTGGAAGGATGATAAG ALCAT1 NT_039658 GTTTGAGGGATGTTGTAAGG 
286 
GAGCACTGGGGAGAAAGGAT CycA NM_017101 CTTGCCATCCAGCCACTCAG 
259 
PGC-1a: peroxisome proliferator activated receptor gamma co-activator 1a; CDS2: CTP: phosphatidic acid 
cytidylyltransferase 2; CPT-1: carnitine palmitoyl transferase I; TAZ: taffazin, ALCAT1: acyl-
CoA:lysocardiolipin acyltransferase 1; CycA: cyclophilin A 
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Table 2. Functional data  
 Wild type (n=5) AMPKa2-/- (n=5) 
 glucose glucose+oleate glucose glucose+oleate 
Ventricular pressure, mmHg 87±7 109±7 85±5 118±6 
Heart rate, beats/min 358±18 317±17 365±9 337±16 
Rate Pressure product, RPP 2.9±0.1 3.2±0.1 2.9±0.2 3.6±0.2 
+DP/dt, mmHg.sec-1 3818±229 4088±264 3778±356 4533±465 
-DP/dt, mmHg.sec-1 -2719±187 -3053±131 -2513±153 -3167±141 
Oxygen consumption rate, QO2 6.4±0.7 8.6±0.7* 6.0±0.6 8.0±1.0 
QO2/RPP 2.3±0.3 2.7±0.3 2.1±0.3 2.3±0.3 
Hearts were first perfused with glucose 11 mM and then with glucose 5 mM and 0.4 mM oleate. Values are 
means ± S.E.M., n = number of mice; RPP: 104.mmHg.beats.min-1. QO2: µmol O2.min
-1.g-1 ww. No statistical 
difference between control and AMPKa2-/-. * p <0.05, glucose versus glucose + oleate.  
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Table 3. Energy metabolism of cardiac fibers  
 Control AMPKa2-/- 
Morphometric data   
Number of hearts 3 3 
Total mitochondria 36.1±1.8 37.6±0.5 
SS mitochondria 3.9±0.4 11.3±1.1* 
IM mitochondria 32.2±1.4 26.3±1.4* 
   
Mitochondrial function   
Number of fibers 20 18 
V0, µmoles O2/min/g dw 3.0±0.3 2.7±0.2 
Vglu+mal, µmoles O2/min/g dw 18±1 13±1* 
Vsuc, µmoles O2/min/g dw 19±2 23±2 
Vsuc/Vglu+mal 1.2±0.1 1.7±0.2* 
Vduroq*, µmoles O2/min/g dw 50±10 54±8 
KmADP 253±54 289±49 
KmCr 73±14 52±11 
ACR 6.2±0.9 4.9±0.4 
   
Enzymatic Activity (IU/mg prot)   
Number of animals 9 8 
Citrate synthase 836±58 742±48 
Cytochrome oxidase 1207±120 1114±114 
Creatine kinase (CK) 2637±182 2860±171 
mi-CK 653±96 716±67 
Adenylate kinase 2107±150 2414±219 
Lactate dehydrogenase 932±75 999±70 
Complex-I (decyl-ubiquinone) 450±64 413±51 
Complex-I (ferricyanure) 990±86 914±77 
Complex-II 264±27 226±21 
Malate dehydrogenase (MDH) 5906±500 5843±573 
Mitochondrial MDH 1913±250 1818±112 
Values are means ± S.E.M., nd: not detectable. Morphological data are expressed in % cell volume. Oxygen 
consumption rates in the absence (V0) and presence of 2mmol/l ADP (Vglu+mal respiration through complex I 
with glutamate+malate; Vsuc respiration through complex II with succinate,); Vduroq respiration through 
complex III with reduced duroquinol *(n=10 for each). Michaelis-Menten constant of respiration rate for ADP 
(µmol/l) without (Km) or with (KmCr) 20mmol/l creatine. ACR: acceptor control ratio (Vglu+mal/V0). * p <0.05, 
versus control mice.  
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Table 4. Fatty acid composition of cardiac lipids  
Values are means ± S.E.M. *, p<0.05. SFA: saturated fatty acids. MUFA, mono-unsaturated fatty acids. PUFA: 
polyunsaturated fatty acids. LA, linoleic acid. Three control and three AMPKa2-/- mice were used.  
COMPOSITION (%) 
Heart Mitochondria Heart Phospholipids Non phosphorous Lipids     Fatty acid 
Control AMPKa2-/- Control AMPKa2-/- Control AMPKa2-/- 
16:0 13.4±0.6 14.6±0.7 14.2±0.9 16.4±0.5 19.8±0.5 18.1±0.4 
16:1 w9 1.1±0.2 1.0±0.3 0.3±0.1 0.35±0.03 6.2±0.7 4.5±0.3 
18:0 18±1 17±1 21±1 21±1 8.9±0.3 9±1 
18:1 w9 6.7±0.3 7.0±0.2 6.3±0.3 6.3±0.3 19.0±0.4 22.0±0.4* 
18:1 w7 2.51±0.03 2.7±0.1 2.26±0.04 2.5±0.1 1.4±0.1 1.5±0.3 
18:2 w6 LA 19.2±0.6 16.8±0.4* 18.0±0.2 16.3±0.5* 20.1±1.5 24.3±0.3* 
20:4 w6 4.5±0.2 4.3±0.2 5.2±0.2 4.9±0.3 3.0±0.1 2.6±0.4 
22:5 w3 1.02±0.03 1.2±0.1 1.1±0.1 4.1±3.1 1.5±0.1 1.5±0.4 
22:6 w3 30±2 31±2 28±2 24±1 5.1±0.4 5.4±0.6 
SFA 32±1 33±1 36±2 34±5 36±1 39±5 
MUFA 12±1 11±1 9.7±0.3 9±1 31±1 36±6 
PUFA w6 25.1±0.5 22.5±0.6* 25.2±0.4 20±3 25±1 33±5 
PUFA w3 31±2 33±2 29±2 24±4 8.1±0.3 9±1 
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